Biota Pharmaceuticals to Present at 15th Annual Needham Healthcare Conference
April 06 2016 - 9:00AM
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical
company focused on the discovery and development of direct-acting
antivirals that address infections that have limited therapeutic
options, announced today that Biota’s CEO & President Joseph
Patti, PhD will present a corporate overview and update at the 15th
Annual Needham Healthcare Conference on Wednesday, April 13, 2016
at 10:00 a.m. ET in New York.
A live webcast of the presentation can be accessed
under “Events and Presentations” in the Investors section of the
Company’s website at www.biotapharma.com or at
http://wsw.com/webcast/needham76/bota.
A replay of the webcast will be archived for 30
days following the presentation.
About Biota Pharmaceuticals,
Inc.
Biota Pharmaceuticals is focused on the discovery
and development of direct-acting antivirals to treat infections
that have limited therapeutic options and affect a significant
number of patients globally. The Company has three product
candidates in active clinical development: These include
vapendavir, an oral treatment for human rhinovirus infections in
moderate-to-severe asthmatics currently being evaluated in the
Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion
protein inhibitor that has received Fast Track designation by the
U.S. FDA, in Phase 2 development for the treatment and prevention
of respiratory syncytial virus (RSV) infections; and BTA074, a
topical antiviral treatment in Phase 2 development for condyloma
caused by human papillomavirus types 6 & 11. For additional
information about the Company, please visit
www.biotapharma.com.
Biota is a registered trademark of Biota
Pharmaceuticals, Inc.
Contact:
Mark Colonnese
Executive Vice President and Chief Financial Officer
(678) 221-3381
m.colonnese@biotapharma.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024